VORSCHAU

PRESSETERMINE

AKTUELLES PRESSEFOTO



WETTER
Graz: bedeckt
24°
Innsbruck: Regen
22°
Linz: Regen
22°
Wien: bedeckt
20°
© wetter.net

Stadtname / PLZ

AKTIENKURSE
 
ADHOC
Di, 01.02.2022 18:45
Meldung drucken Artikel weiterleiten
pta20220201049
Public disclosure of inside information according to article 17 MAR
Pressefach Pressefach

4SC AG: 4SC AG – Discontinuation Domatinostat Program

Planegg-Martinsried (pta049/01.02.2022/18:45) - Planegg-Martinsried, Germany, 1 February 2022 – The Management Board and Supervisory Board of 4SC AG (FSE Prime Standard: VSC) today decided that as a result of a review of more recent clinical data 4SC discontinues the development program for domatinostat, an orally administered small molecule class I selective HDAC inhibitor.

4SC will now focus its resources completely on resminostat and on seeing an outcome to the ongoing pivotal RESMAIN study in CTCL and prepare for its commercialization in case of positive data. 4SC continues to be well funded and expects to have sufficient cash in-hand to obtain topline results from the RESMAIN study.

—————————————————————————
Information and Explanation of the Issuer to this News:

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

Jason Loveridge, PhD

CEO

ir-pr@4sc.com
+49 89 700763-0

(Ende)

Aussender: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Deutschland
Ansprechpartner: Jason Loveridge
Tel.: +49 89 700763-0
E-Mail:
Website: www.4sc.de
ISIN(s): DE000A3E5C40 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
4SC AG
   
So wurde bewertet:
Weitersagen
Share Share |
Social Media
ETARGET

FOCUSTHEMA


SPECIALS


Werbung
middleAdvertising